| Revenue, net | 221.9a | 9.3a | 77.65a |
| Operating costs and expenses | — | — | — |
| Cost of revenue | -3.88a | -2.45a | -3.43a |
| Research and development | -506.46a | -455.71a | -399.46a |
| Selling, general and administrative | -288.93a | -150.59a | -143.19a |
| Restructuring, impairment and related charges | -15.61a | -7.93a | -43.77a |
| Total operating costs and expenses | -814.88a | -616.67a | -589.85a |
| Loss from operations | -592.97a | -607.37a | -512.2a |
| Other income (expense), net | — | — | — |
| Interest income | 17.25a | 18.04a | 7.54a |
| Interest expense, net | -99.29a | -81.29a | -80.44a |
| Gain on deconsolidation of subsidiaries | 178.32a | 0a | 0a |
| Loss on extinguishment of debt | -26.59a | 0a | 0a |
| Net loss from equity method investments | -31.18a | 0a | 0a |
| Gain from sale of priority review voucher, net | 0a | 0a | 107.95a |
| Other income (expense), net | 12.27a | 17.37a | -7.5a |
| Total other income (expense), net | 50.78a | -45.88a | 27.55a |
| Loss before income taxes | -542.19a | -653.25a | -484.65a |
| Income tax expense | -1.15a | 0a | 0a |
| Net loss | -543.35a | -653.25a | -484.65a |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 7.59a | 10.05a | 3.47a |
| Net loss attributable to common stockholders of BridgeBio | -535.76a | -643.2a | -481.18a |